10-Q: Black Hawk SPAC Nears Vesicor Merger Amid Liquidity Crisis

Black Hawk Acquisition Corporation has entered a definitive agreement to merge with biotech firm Vesicor Therapeutics, valuing it at $70 million, but faces significant shareholder redemptions and going concern doubts.

Summary

• Entered into a Business Combination Agreement with Vesicor Therapeutics, Inc. on April 26, 2025, valuing Vesicor at a pre-money equity value of $70 million.
• Vesicor shareholders will roll over 100% of their equity into the combined company, which will be named Vesicor and listed on Nasdaq.
• Shareholders approved an extension of the business combination deadline monthly through December 22, 2026, requiring $150,000 monthly deposits into the Trust Account.
• 4,775,923 public ordinary shares were redeemed, resulting in a $51.0 million payment from the Trust Account, leaving approximately $22.7 million.
• The company had cash of $15,000 and a working capital deficit of $901,638 as of August 31, 2025.
• Management has determined that conditions raise substantial doubt about the company's ability to continue as a going concern.
• Net income for the three months ended August 31, 2025, was $154,401, a decrease from $883,767 in the same period of 2024.
• Net income for the nine months ended August 31, 2025, was $1,333,322, an increase from $1,164,002 in the same period of 2024, primarily due to interest income from the Trust Account.

Sentiment

Score: 3

Explanation: The company has secured a business combination agreement and an extension, which are positive steps for a SPAC. However, the very high redemption rate, severe liquidity issues, going concern doubt, and ineffective internal controls present significant challenges and risks, indicating a highly precarious financial position and operational concerns.

Positives

• Secured a definitive Business Combination Agreement with Vesicor Therapeutics, an early development stage biotech company focused on p53-based cancer therapeutics.
• Shareholders approved the extension of the business combination deadline until December 22, 2026, providing more time to complete the merger.
• Vesicor Therapeutics made non-refundable deposits totaling $250,000 into the company's operating account to cover transaction costs.
• Net income for the nine months ended August 31, 2025, increased to $1,333,322 from $1,164,002 in the prior year period, driven by interest income from the Trust Account.

Negatives

• Experienced significant shareholder redemptions of 4,775,923 public ordinary shares, resulting in a $51.0 million payment from the Trust Account and a substantial reduction in available funds.
• Cash balance significantly decreased to $15,000 as of August 31, 2025, from $264,842 on November 30, 2024.
• Reported a working capital deficit of $901,638 as of August 31, 2025.
• Management has determined that conditions raise substantial doubt about the company's ability to continue as a going concern.
• Net income for the three months ended August 31, 2025, decreased to $154,401 from $883,767 in the same period of 2024.
• Disclosure controls and procedures were concluded to be not effective at a reasonable assurance level as of August 31, 2025.
• General and administrative expenses for the nine months ended August 31, 2025, increased to $607,632 from $420,863 in the prior year period.

Risks

• Substantial doubt exists about the company's ability to continue as a going concern due to limited cash and a significant working capital deficit.
• Failure to complete the Business Combination within the extended Combination Period would lead to liquidation, with public shares redeemed at a per-share price from the Trust Account, potentially less than $10.05 per share.
• Global social and political circumstances (e.g., trade tensions, Russia/Ukraine, Hamas/Israel conflicts) may adversely affect the ability to consummate a Business Combination or the operations of the target business.
• The ability to raise equity and debt financing may be impacted by increased market volatility or decreased market liquidity, potentially hindering the completion of the Business Combination.
• The Sponsor's liability for claims reducing Trust Account funds below $10.05 per Public Share has exceptions, meaning public shareholders might not be fully protected.
• Rights will expire worthless if the Business Combination is not completed within the Combination Period.
• Inherent limitations on the effectiveness of internal controls mean misstatements due to error or fraud may occur and not be detected.

Future Outlook

The Business Combination with Vesicor Therapeutics is expected to be completed by the fourth quarter of 2025. The company has secured the ability to extend the business combination deadline monthly through December 22, 2026, by making required $150,000 monthly deposits into the Trust Account. Significant professional and transaction costs are anticipated in pursuit of the Business Combination.

Management Comments

• Management has determined that these conditions raise substantial doubt about the Company's ability to continue as a going concern.
• Our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures were not effective at a reasonable assurance level as of August 31, 2025.

Industry Context

This filing highlights the inherent challenges and typical lifecycle of a Special Purpose Acquisition Company (SPAC), particularly the significant shareholder redemptions often seen when a SPAC seeks an extension or announces a business combination. The target, Vesicor Therapeutics, operates in the early development stage biotechnology sector, specifically in p53-based cancer therapeutics, a high-risk, high-reward area. The substantial redemptions indicate a lack of confidence from a large portion of public shareholders in either the SPAC's management, the proposed target, or the broader SPAC market sentiment, which has been volatile. The need for multiple extensions and related party financing underscores the difficulties in completing DeSPAC transactions in the current market.

Comparison to Industry Standards

• The high redemption rate of 4,775,923 shares (approximately 69% of public shares) is significantly higher than the historical average for SPACs, which typically ranged from 50-70% in 2022-2023, but can be much higher for less attractive deals or in challenging market conditions. This indicates substantial shareholder dissatisfaction or a preference for redemption over participation in the proposed merger.
• The valuation of Vesicor Therapeutics at a $70 million pre-money equity value for an early development stage biotechnology company is within the typical range for such firms, but its attractiveness depends heavily on the strength of its p53-based cancer therapeutics pipeline and clinical data, which are not detailed in this filing.
• The reliance on sponsor loans and monthly extension payments of $150,000 to maintain the Trust Account is a common, but often concerning, practice for SPACs struggling to close a deal, reflecting a drain on sponsor capital and potentially indicating a less attractive deal for public shareholders.
• The disclosure of ineffective disclosure controls and procedures is a significant governance red flag, contrasting negatively with best practices for public companies and potentially signaling broader operational weaknesses.

Management Changes

Corporate Governance

Related Party Transactions

• The Sponsor (Black Hawk Management LLC) was issued Founder Shares for $25,000.
• The Company pays the Sponsor $10,000 per month for office space and administrative services under an Administrative Services Agreement.
• The Company issued a convertible note to the Sponsor on June 13, 2025, for up to $350,000 with a 6% annual interest rate.
• The Company issued another convertible note to the Sponsor on September 23, 2025, for up to $350,000 with a 10% annual interest rate.
• The Sponsor or its affiliates may loan additional funds to the Company for transaction costs.

Stakeholder Impact

• Shareholders: Significant redemptions have reduced the Trust Account balance and the number of public shares outstanding. Remaining shareholders face uncertainty regarding the completion of the Business Combination and the company's going concern status. Those who redeemed received approximately $10.68 per share.
• Sponsor: Continues to provide financial support through convertible notes and extension payments, increasing its exposure and commitment to the Business Combination.
• Vesicor Therapeutics: The proposed merger offers a path to public listing and access to capital, but the SPAC's liquidity issues and high redemptions could impact the final deal structure or combined entity's financial strength.
• Underwriters: Entitled to a deferred fee of $2,415,000 upon closing of a Business Combination, which is contingent on the deal's success.

Next Steps

• Complete the domestication of the company from Cayman Islands to Delaware.
• Merge Merger Sub with Vesicor Therapeutics, Inc.
• Obtain regulatory approvals for the Business Combination.
• Obtain shareholder approvals for the Business Combination.
• Secure Nasdaq approval for the listing application of the combined company.
• Complete the Business Combination by the fourth quarter of 2025.
• Continue making $150,000 monthly deposits into the Trust Account to extend the business combination deadline, if necessary, until December 22, 2026.

Key Dates

Recommendation

The company faces severe liquidity challenges, evidenced by a cash balance of $15,000 and a working capital deficit of over $900,000. Management has explicitly raised substantial doubt about the company's ability to continue as a going concern. While a business combination agreement with Vesicor Therapeutics has been signed, the extremely high redemption rate (approximately 69%) indicates a significant lack of investor confidence in the deal or the SPAC itself. The reliance on repeated sponsor loans for extensions and working capital, coupled with the disclosure of ineffective disclosure controls, points to fundamental operational and financial weaknesses. The risk of liquidation if the business combination fails, potentially at a per-share value less than $10.05, is high. Given these factors, the investment carries substantial risk, and a seasoned investor would likely recommend selling to avoid further potential losses.

Keywords

SPAC, Black Hawk Acquisition Corporation, Vesicor Therapeutics, Business Combination, DeSPAC, Biotechnology, Cancer Therapeutics, SEC Filing, 10-Q, Going Concern, Shareholder Redemptions, Trust Account, Extension, Nasdaq